Glenn D. Hoke, Ph.D. – Chief Executive Officer
Dr. Hoke joined Theranostics Health as its Chief Operating Officer in September, 2009. Dr. Hoke is responsible for the managing of the Company’s scientific and service delivery operations, fundraising, and strategic direction. He previously served as Executive Vice President and Chief Scientific Officer while at Dyad Pharmaceutical Corporation (2003-2009). At Dyad, he managed the preclinical development of the company’s lead therapeutics, Prior to Dyad, while Vice President Research and Development at Gene Logic, Inc. (1998-2003), Dr. Hoke led research and development efforts on a number of platform technologies. Prior to Gene Logic, he was Vice President at Genetic MediSyn (1993-1998), the drug discovery arm of SyntheCell. Before Genetic MediSyn, Dr. Hoke was employed at Isis Pharmaceuticals (1989-1993). Prior to his tenure at Isis, he worked as a joint appointee in the Departments of Molecular Pharmacology and Investigative Toxicology at SmithKline and French Research Laboratories (1986-1989). Dr. Hoke received his doctorate (1986) Biochemistry at the Medical College of Virginia, Virginia Commonwealth University; a B.S. in biology (1974) from Virginia Polytechnic Institute and State University; and a master’s degree in biology (1979) from Virginia Commonwealth University.
Ron Hencin, Ph.D. – Vice President of Business Development
Dr. Hencin joined the Company in December, 2009. Previously, he was Vice President of BioResearch Sales for Gene Logic, an Ocimum Biosolutions company. During his nine years with Gene Logic, he led the business development efforts for worldwide Genomic Services including gene expression and SNP profiling, bioinformatics data analysis, and clinical biomarker discovery. He managed the direct sales of genomic services to major pharmaceutical and biotech corporations worldwide and possesses a broad experience base in strategic sales, sales management, and marketing coupled with operational experience in taking start-up companies through financing, mergers and acquisitions.
Prior to Gene Logic, Dr. Hencin spent 12 years as an entrepreneur and executive in the IT industry. He co-founded and managed three software development companies focused on commercial applications of Artificial Intelligence technology. These companies brought to market award-winning commercial software product lines for expert systems, affinity portals, data mining, and content management solutions. He has a BS in Biology from Yale University and a Ph.D. in Microbiology from the University of Florida.
Corinne Ramos, Ph.D. – Executive Director of Clinical Research
Dr. Ramos has been with Theranostics since July, 2008 and directs the company’s pharmaceutical service business. Dr. Ramos brings a strong background in experimental design and the technologies related to image capture and analysis. She has over 7 years experience in the field of proteomics and biochemistry while serving as a project scientist at the University of California, San Diego, and at the National Institute of Health. In addition to her scientific expertise, she has a background in financial management and is currently completing her MBA, with a focus on corporate finance and strategy.
John Hartwell, MBA – Senior Director of Sales and Marketing
Mr. Hartwell joined the Company in December, 2009. Previously, he was Business Development Director at Gene Logic where he had created and managed a network of local sales agents in the Asia Pacific region, as well as direct sales and marketing efforts aimed at key European and North American pharmaceutical companies. Mr. Hartwell also has 12 years of progressive R&D experience in the fields of proteomics, genomics and molecular genetics at various commercial, government and academic institutions (Gene Logic, Genzyme Transgenics, Dyad Pharmaceutical, VA Medical Center in Baltimore, University of Maryland at Baltimore, Clemson University and the Greenwood Genetics Center), along with a decade of sales and marketing experience involving genomic and proteomic products and services to biotech and pharmaceutical companies. His educational background includes both a Bachelor of Science in Microbiology from Clemson University and a Master of Business Administration from the University of Maryland.